Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3056)	7/27/2010 2:12:40 PM
From: Jibacoa	Respond to of 3722

OGXI was up 15.06% but it is up only 13.97% at present.<g> bigcharts.marketwatch.com The stock has resistance at the June 25 H of $14.72 and then at the $15 level.<g> On June 21 It announced that it is starting a PIII of custirsen sodium, the first of three trials it will undertake in a deal with TEVA.<g> OGXI said the first PIII will be conducted at about 50 cancer centers and will enroll about 300 men with metastatic, hormonal resistance, prostatic Cas. The ACTAY is $43.43 <g> It seems that with some good news and a close above $15, the stock could get back to the $20 level. That's where I would place a TT.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (3056)	12/7/2010 10:26:20 AM
From: Jibacoa	Respond to of 3722

ONXX was up 14.11% and is still up 11.45 on volume about 1.5x its ADV The stock opened with an UG after it made some announcements at the ASH meeting in Orlando.<g> It announced that carfilzomib shrank the tumors of one-third of study patients with MM. On 257 patients who had failed to improve on previous treatments, 24% had their tumors reduced by half while 10% had malignancy reduced by 1/4 The reduction in tumor size was maintained for a median of eight months.<g> The ACTAY is $34.64 With some good news the stock could get to the $40 or $45 level. I will keep a TT at $40 pending further developments.<g> bigcharts.marketwatch.com Bernard